Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies

Area of Science:

• Oncology
• Immunology
• Hepatology

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally, with limited survival improvements for advanced stages.
• While tyrosine kinase inhibitors (TKIs) offer some benefit, immune checkpoint inhibitors (ICIs) have recently emerged as a revolutionary palliative care option for HCC.
• However, a significant proportion of HCC patients do not respond to current immunotherapies, highlighting an unmet clinical need.

Purpose of the Study:

• To provide a comprehensive overview of the immune landscape in normal liver, cirrhotic liver, and the HCC tumor microenvironment.
• To discuss molecular and immunological classifications of HCC, focusing on the role of myeloid cells in anti-tumor immunity, tumor promotion, and immune evasion.
• To explore current challenges and future opportunities for immunotherapies in HCC management.

Main Methods:

• Literature review and synthesis of existing research on HCC immunology and microenvironment.
• Analysis of immune cell subsets, particularly myeloid cells, and their functions in HCC pathogenesis.
• Discussion of emerging therapeutic strategies, including cell-based therapies, oncolytic viruses, and combination treatments.

Main Results:

• The immune microenvironment of the liver and HCC is complex, influencing treatment response.
• Myeloid cells play multifaceted roles in HCC, contributing to both anti-tumor immunity and immune evasion.
• Understanding HCC's immunological classifications is crucial for predicting and improving immunotherapy outcomes.

Conclusions:

• Despite advances, significant challenges remain in optimizing immunotherapy for HCC patients.
• Harnessing the potential of myeloid cells, NK cells, and γδ T cells offers promising therapeutic avenues.
• Novel strategies like CAR-T/NK cells, oncolytic viruses, and combination therapies are critical for advancing HCC treatment.